3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Sarcoma
2
Other solid neoplasm
2
Gastrointestinal
2
NET
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
105
Carcinoma, Hepatocellular
34
Gastrointestinal Stromal Tumors
17
Colonic Neoplasms
14
Rectal Neoplasms
12
Neoplasm Metastasis
12
Liver Neoplasms
8
Stomach Neoplasms
5
Cholangiocarcinoma
5
Pancreatic Neoplasms
4
Esophageal Neoplasms
4
Sarcoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Colorectal Cancer Metastatic
3
Carcinoma, Renal Cell
3
Advanced Colorectal Cancer
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Lung Neoplasms
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Cancer Liver Metastases
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
Cyclophosphamide
4
pembrolizumab
3
Nivolumab
3
regorafenib
2
fludarabine
2
SS1(dsFv)PE38
2
Ipilimumab
2
Hyperthermic Intraperitoneal Chemotherapy
2
Doxorubicin
2
Decitabine
2
Cisplatin
2
tislelizumab
1
sodium thiosulfate
1
sargramostim
1
entinostat
1
durvalumab
1
cemiplimab
1
bemcentinib
1
avelumab
1
atezolizumab
1
alvocidib
1
alanosine
1
X-Rays
1
Tetrahydrouridine
1
Tamoxifen
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Specimen Handling
1
Referral and Consultation
1
Radiotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
regorafenib
×
Gastrointestinal
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled